Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2022-003725-22
    Sponsor's Protocol Code Number:KKS-306
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2023-01-26
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2022-003725-22
    A.3Full title of the trial
    Acute effect of iloprost (Ventavis®) inhalation in patients with exercise-induced pulmonary hypertension after a COVID-19 infection
    Akute Wirkung von Iloprost (Ventavis)®-Inhalation bei Patienten mit belastungsinduzierter pulmonaler Hypertonie nach einer COVID-19-Infektion
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Acute effect of iloprost inhalation on pulmonary hypertension developed during exercise in Post-COVID-19 patients
    Akute Wirkung der Inhalation mit Iloprost bei Lungenhochdruck unter Belastung nach einer COVID-19-Infektion
    A.3.2Name or abbreviated title of the trial where available
    IXite
    A.4.1Sponsor's protocol code numberKKS-306
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJustus-Liebig-University Gießen
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBMBF
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCoordinating Center for Clinical Trials of the Philipps-University Marburg
    B.5.2Functional name of contact pointSandrine Oberwinkler
    B.5.3 Address:
    B.5.3.1Street AddressKarl-von-Frisch-Straße 4
    B.5.3.2Town/ cityMarburg
    B.5.3.3Post code35043
    B.5.3.4CountryGermany
    B.5.4Telephone number+4964212866503
    B.5.5Fax number+4964212866517
    B.5.6E-mailixite@kks.uni-marburg.de
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ventavis
    D.2.1.1.2Name of the Marketing Authorisation holderBayer AG
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Nebulisation solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIloprost
    D.3.9.1CAS number 78919-13-8
    D.3.9.4EV Substance CodeSUB08136MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg/ml microgram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Exercise-induced pulmonary hypertension after a COVID-19 infection
    Belastungsinduzierte pulmonale Hypertonie nach einer COVID-19-Infektion
    E.1.1.1Medical condition in easily understood language
    Pulmonary hypertension developed during exercise by patient with a Long-COVID-19 infection
    Lungenhochdruck unter Belastung nach einer Long-COVID-19-Infektion
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10037400
    E.1.2Term Pulmonary hypertension
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 24.1
    E.1.2Level LLT
    E.1.2Classification code 10085867
    E.1.2Term Post-COVID-19 syndrome
    E.1.2System Organ Class 100000004862
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 24.1
    E.1.2Level LLT
    E.1.2Classification code 10085868
    E.1.2Term Long COVID-19
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The objective of this study is to assess the therapeutic approach using the inhaled prostanoid iloprost (Ventavis®) in a feasibility study in patients with exercise- induced pulmonary hypertension after an infection with COVID-19. The goal is therefore to evaluate the tolerability of the drug by the patients (identify potential side-effects, which might appear upon treatment), to determine the changes in pulmonary vascular resistance under exercise and changes in exercise capacity after treatment, and to estimate the number of patients eligible for this treatment strategy in order to plan future placebo-controlled trials.
    The primary objective is to determine the changes in pulmonary hemodynamics after treatment with Ventavis®.
    Ziel der Studie ist es, den therapeutischen Ansatz mit dem inhalativen Prostanoid Iloprost (Ventavis®) in einer Machbarkeitsstudie für Patienten mit belastungsinduzierter pulmonaler Hypertonie nach einer COVID-19-Infektion zu bewerten. Ziel sind daher, die Verträglichkeit des Medikaments bei den Patienten zu bewerten (Ermittlung potenzieller Nebenwirkungen, die bei der Behandlung auftreten könnten), die Veränderungen des pulmonalen Gefäßwiderstands unter Belastung und der körperlichen Leistungsfähigkeit nach der Behandlung zu bestimmen und die Zahl der Patienten zu schätzen, die für diese Behandlungsstrategie in Frage kommen, um künftige placebokontrollierte Studien zu planen.
    Primäres Ziel ist die Bestimmung der Veränderungen in der pulmonalen Hämodynamik.

    E.2.2Secondary objectives of the trial
    The secondary objectives are to assess the exercise-induced changes (maximal exercise capacity, gas exchange, ventilatory efficiency), the transpulmonary gradient and the pulmonary venous congestion after treatment with Ventavis® and to assess toxicity and safety of Ventavis® treatment.
    Die sekundären Ziele sind die Erfassung der Veränderungen der maximalen körperlichen Leistungsfähigkeit (maximale Belastbarkeit, Gasaustausch, präkapillare ventilatorische Effizienz), des transpulmonalen Gradienten und der pulmonalvenösen Stauung nach der Behandlung mit Ventavis® und die Bewertung der Sicherheit der Ventavis®-Behandlung.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    All inclusion criteria will be verified after the signature of the informed consent on Day 0 and before the first right heart catheter exercise phase except criterion 5, which will be checked on Day 1 after the first right heart catheter exercise phase.

    1. Patient must be ≥ 18 years old
    2. Signed informed consent
    3. Patients with Post-COVID-19-Syndrome (persistent dyspnea longer than 12 weeks after a COVID-19 infection)
    4. Patients with non-invasive signs of manifest or exercise-induced pulmonary hypertension (PH)
    5. Exercise-induced PH determined by a mPAP/CO-slope > 3 mmHg/l/min between rest and exercise. This inclusion criterion will be checked on Day 1 on the basis of the result of the first RHC exercise phase.
    6. Willingness of men and women of childbearing potential to use highly effective contraceptive methods.
    Such methods include:
    • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
    o oral
    o intravaginal
    o transdermal
    • progestogen-only hormonal contraception associated with inhibition of ovulation:
    o oral
    o injectable
    o implantable
    • intrauterine device (IUD)
    • intrauterine hormone-releasing system (IUS)
    • bilateral tubal occlusion
    • vasectomised partner
    • sexual abstinence




    Einschlusskriterien:
    Alle Einschlusskriterien werden nach der Unterzeichnung der Einwilligungserklärung am Tag 0 und vor der ersten Rechtsherzkatheter Untersuchung überprüft, mit Ausnahme von Kriterium 5, das am ersten Tag nach der ersten Rechtsherzkatheter Belastungsphase überprüft wird.

    1. Der Patient muss ≥ 18 Jahre alt sein
    2. Unterzeichnete Einverständniserklärung
    3. Patienten mit Post-COVID-19-Syndrom (anhaltende Dyspnoe länger als 12 Wochen nach einer COVID-19-Infektion)
    4. Patienten mit nicht-invasiven Anzeichen einer manifesten oder belastungsinduzierten pulmonalen Hypertonie (PH)
    5. Belastungsinduzierte pulmonale Hypertonie, bestimmt durch einen mPAP/CO-Slope > 3 mmHg/l/min zwischen Ruhe und Belastung. Dieses Einschlusskriterium wird am Tag 1 anhand des Ergebnisses der ersten Rechtsherzkatheter Untersuchung überprüft.
    6. Bereitschaft von Männern und Frauen im gebärfähigen Alter, hochwirksame Verhütungsmethoden anzuwenden. Diese Methoden umfassen:
    - kombinierte (Östrogen- und Gestagen haltige) hormonelle Verhütungsmethoden, die mit einer Hemmung des Eisprungs verbunden sind: oral, intravaginal, transdermal
    - hormonelle Empfängnisverhütung mit ausschließlichem Gestagen, die mit einer Hemmung des Eisprungs einhergeht:
    oral, injizierbar, implantierbar
    - Intrauterinpessar (IUP)
    - Intrauterinpessar mit Hormonfreisetzung (IUS)
    - Beidseitiger Eileiterverschluß
    - vasektomierter Partner
    - sexuelle Abstinenz




    E.4Principal exclusion criteria
    All exclusion criteria will be verified after the signature of the informed consent on Day 0, except criterion 1, which will be checked on Day 1 after the first right heart catheter exercise phase.

    1. Hypercirculation (CI> 4.0 l/min/m2) or evidence of postcapillary PH (PAWP/CO-slope> 2 mm Hg/l/min). This exclusion criterion will be checked on Day 1 on the basis of the result of the first RHC exercise phase.
    2. Preexisting clinically relevant lung disease (FEV 1< 60% pred., FVC < 60% pred., RV/TLC> 40%), radiologic signs of moderate to severe pulmonary emphysema
    3. Severe coronary artery disease or unstable angina (history of surgery, history of coronary intervention two years prior to inclusion), history of myocardial infarction within the last six months, uncontrolled arterial hypertension, pulmonary hypertension due to pulmonary veno-occlusive disease, severe left ventricular hypertrophy, congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension, decompensated heart insufficiency if not under close medical control, history of stroke/transitory ischemic attack with the last three months prior to inclusion, systolic blood pressure below 85 mmHg, severe arrhythmias
    4. Concomitant use of specific phosphodiesterase inhibitors (e.g. sildenafil, vardenafil, or tadalafil), endothelin antagonists (e.g. ambrisentan or macitentan), or intravenous prostacyclin; inhibitors of platelet aggregation or anticoagulants. The use of these substances needs to be stopped at least 8 weeks prior to study start.
    5. Inability to perform cardiopulmonary exercise testing (CPET), including temporary orthopedic problems
    6. Hemoglobin < lower limit of normal (LLN)
    7. Treatment with any investigational drug within 30 days prior to inclusion
    8. Pregnancy or breastfeeding
    9. Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of results, incl. limited effort in spiroergometry (CPET).
    10. Hypersensitivity to the active substance
    or any of the other ingredients
    11. Situations where the effect of Ventavis® on platelets may increase the risk of bleeding (e.g. florid ulcer disease, trauma, intracranial bleeding)
    12. Patients with severe impaired liver function: Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥ 3 × the upper limit of the normal range (ULN) at screening, bilirubin ≥ 3 mg/dL at screening (except for patients with Gilbert‘s syndrome)
    13. Patients with severe impaired kidney function (creatinine clearance ≤ 30 ml/min)
    14. Simultaneous participation in another clinical trial with an experimental treatment
    15. Pulmonal veno-occlusive disease
    Ausschlusskriterien:
    Alle Ausschlusskriterien werden nach Unterzeichnung der Einverständniserklärung am Tag 0 überprüft, mit Ausnahme von Kriterium 1, das am Tag 1 nach der ersten Rechtsherzkatheter-Belastungsphase überprüft wird.

    1. Hyperzirkulation (CI> 4,0 l/min/m2) oder Nachweis einer postkapillären PH (PAWP/CO-Slope> 2 mm Hg/l/min). Dieses Ausschlusskriterium wird am Tag 1 anhand des Ergebnisses der ersten Rechtsherzkatheter Belastungsphase überprüft.
    2. Vorbestehende klinisch relevante Lungenerkrankung (FEV 1< 60% des Soll, FVC < 60% des Soll, RV/TLC> 40%), radiologische Anzeichen eines mittelschweren bis schweren Lungenemphysems
    3. Schwere koronare Herzkrankheit oder instabile Angina pectoris (Operation in der Vorgeschichte, Koronarintervention in der Vorgeschichte zwei Jahre vor dem Einschluss), Myokardinfarkt in der Vorgeschichte innerhalb der letzten sechs Monate, unkontrollierte arterielle Hypertonie, pulmonale Hypertonie aufgrund einer pulmonalen veno-okklusiven Erkrankung, schwere linksventrikuläre Hypertrophie, angeborene oder erworbene Klappendefekte mit klinisch relevanten myokardialen Funktionsstörungen, die nicht mit einer pulmonalen Hypertonie assoziiert sind, dekompensierte Herzinsuffizienz, wenn sie nicht unter strenger ärztlicher Kontrolle steht, Schlaganfall/transitorische ischämische Attacke in den letzten drei Monaten vor dem Einschluss, systolischer Blutdruck < 85 mm Hg, schwere Arrhythmien
    4. Gleichzeitige Anwendung von spezifischen Phosphodiesterase-Hemmern (z. B. Sildenafil, Vardenafil oder Tadalafil), Endothelin-Antagonisten (z. B. Ambrisentan oder Macitentan) oder intravenösem Prostazyklin, Thrombozytenaggregationshemmern oder Antikoagulanzien. Die Einnahme dieser Substanzen muss mindestens 8 Wochen vor Beginn der Studie eingestellt werden.
    5. Unfähigkeit, kardiopulmonale Belastungstests (CPET) durchzuführen, einschließlich vorübergehender orthopädischer Probleme
    6. Hämoglobin < untere Grenze der Norm
    7. Behandlung mit einem Prüfpräparat innerhalb von 30 Tage vor dem Einschluss in die Studie
    8. Schwangerschaft oder Stillen
    9. Alle bekannten Faktoren oder Krankheiten, die die Einhaltung der Behandlung, die Durchführung der Studie oder die Interpretation der Ergebnisse beeinträchtigen könnten, einschließlich begrenzte Belastbarkeit des Patienten bei der Spiroergometrie (CPET).
    10. Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile
    11. Situationen, in denen die Wirkung von Ventavis® auf die Blutplättchen das Blutungsrisiko erhöhen kann (z. B. floride Ulkuskrankheit, Trauma, intrakranielle Blutungen)
    12. Patienten mit stark eingeschränkter Leberfunktion (Aspartat-Aminotransferase (AST) und/oder Alanin-Aminotransferase (ALT) im Serum ≥ 3 × die obere Grenze des Normalbereichs beim Screening, Bilirubin ≥ 3 mg/dL beim Screening (außer bei Patienten mit Gilbert-Syndrom)
    13. Patienten mit stark eingeschränkter Nierenfunktion (Kreatinin-Clearance < 30 ml/min)
    14. Gleichzeitige Teilnahme an einer anderen klinischen Studie mit einer experimentellen Behandlung
    15. Pulmonale venös-okklusive Erkrankung

    E.5 End points
    E.5.1Primary end point(s)
    Primary endpoint assessment:
    Change in pulmonary hemodynamics during exercise shown by the mPAP/CO-slope and determined by right heart catheterization (RHC)
    Bewertung des primären Endpunkts:
    Veränderung der pulmonalen Hämodynamik während der Belastung, dargestellt durch die mPAP/CO-Slope und bestimmt durch eine Rechtsherzkatheteruntersuchung (RHC)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day 1
    Tag 1
    E.5.2Secondary end point(s)
    Secondary endpoint assessment:
    • Change in maximal exercise capacity: VO2max, determined by spiroergometry (CPET)
    • Change in the pulmonary venous system: PAWP/CO-slope, determined by RHC
    • Change in the precapillary system: TPG/CO-slope, determined by RHC
    • Change in ventilation: VE/VCO2 determined by CPET
    • Change in gas exchange and ventilatory efficiency: AaDO2 at max. exercise, PetCO2, EQO2 at the ventilatory threshold, all determined by CPET
    • Toxicity and safety of Ventavis® treatment
    Sekundäre Endpunktbewertung:
    • Veränderung der maximalen körperlichen Leistungsfähigkeit: VO2max, bestimmt durch Spiroergometrie (CPET)
    • Veränderung des pulmonal-venösen Systems: PAWP/CO- Slope, bestimmt durch RHK
    • Veränderung des präkapillaren Systems: TPG/CO-Slope, bestimmt durch RHK
    • Veränderung der Hyperventilation: VE/VCO2, bestimmt durch CPET
    • Veränderung des Gasaustauschs und der ventilatorischen Effizienz: AaDO2 bei maximaler Belastung, PetCO2, EQO2 an der ventilatorischen Schwelle, alle bestimmt durch CPET
    • Toxizität und Sicherheit der Ventavis®-Behandlung
    E.5.2.1Timepoint(s) of evaluation of this end point
    Change in maximal exercise capacity: VO2max, determined by spiroergometry (CPET): Day 3
    Change in the pulmonary venous system: PAWP/CO slope, determined by RHC: Day 1
    Change in the precapillary system: TPG/CO slope, determined by RHC: Day 1
    Change in ventilation: VE/VCO2 determined by CPET: Day 3
    Change in gas exchange and ventilatory efficiency: AaDO2 at max. exercise, PetCO2, EQO2 at the ventilatory threshold, all determined by CPET: Day 3
    Veränderung der maximalen körperlichen Leistungsfähigkeit: VO2max, bestimmt durch Spiroergometrie (CPET): Tag 3
    Veränderung des pulmonal-venösen Systems: PAWP/CO-Steilheit, bestimmt durch RHC: Tag 1
    Veränderung des präkapillaren Systems: TPG/CO-Steilheit, bestimmt durch RHC: Tag 1
    Veränderung der Hyperventilation: VE/VCO2, bestimmt durch CPET: Tag 3
    Veränderung des Gasaustauschs und der ventilatorischen Effizienz: AaDO2 bei maximaler Belastung, PetCO2, EQO2 an der ventilatorischen Schwelle, alle bestimmt durch CPET: Tag 3
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    last visit of the last subject
    letzter Besuch des letzten Patienten
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 10
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 2
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Treatment after termination (premature or regular) of the study will be decided individually between the investigators and the patients. Best medical care will be given to all patients.
    Die Behandlung nach dem (vorzeitigen oder regulären) Abbruch der Studie wird individuell zwischen den Prüfärzten und den Patienten entschieden
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-03-27
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-04-20
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 18:17:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA